Project Grant R41AI188733
Award Date 9/23/25
Completion Date 3/31/27
Dollars Obligated $309K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $404,539 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Rochester General Hospital. The grant will fund the development and evaluation of a novel Haemophilus influenzae lipoprotein fusion vaccine and vaccine platform. Key research objectives include assessing the immunogenicity and protective efficacy of lipidated and fusion protein constructs against nasopharyngeal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This $314,363 Project Grant was awarded on September 11, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit company based in Austin, Texas. The grant supports the development of a microneedle-based mRNA flu vaccine for transcutaneous immunization. The goal is to create a stable, patient-friendly influenza vaccine delivered through the skin rather than by...
- This $1,486,800 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the unexpected role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against Herpes Simplex Virus (HSV). The research involves engineering a novel single-cycle HSV vaccine strain, isolating potent...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The grant aims to develop two innovative vaccine candidates to prevent pulmonary nontuberculous mycobacterial (NTM) infections, which have surpassed tuberculosis as a global health concern. The research involves screening 13 vaccine...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...